MK-0616
Sponsors
Merck Sharp & Dohme LLC
Conditions
ASCVD - Atherosclerotic Cardiovascular DiseaseHeterozygous Familial Hypercholesterolemia (HeFH)HypercholesterolemiaHyperlipidemiaHeterozygous Familial Hypercholesterolemia in pediatric patients
Phase 1
Phase 2
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia
CompletedCTIS2022-502782-14-00
Start: 2023-09-28End: 2025-04-02Target: 123Updated: 2025-02-20
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia
CompletedCTIS2022-502777-42-01
Start: 2024-01-16End: 2025-07-14Target: 299Updated: 2025-08-15
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
Active, not recruitingCTIS2022-502781-24-01
Start: 2024-06-05Target: 3535Updated: 2025-09-25
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia
CompletedCTIS2023-504920-25-00
Start: 2024-08-23End: 2025-02-27Target: 70Updated: 2025-02-20
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia
Active, not recruitingCTIS2023-504922-20-00
Start: 2024-08-23Target: 583Updated: 2026-01-26
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia
RecruitingCTIS2025-521495-54-00
Start: 2025-12-20Target: 110Updated: 2025-12-04